CJC-1295 no DAC, 2mg/vial

CAS:863288-34-0 SYNONYMS:CJC-1295 without DAC, CJC 1295 w/o DAC, CJC 1295 NO DAC MF:52H252N44O42 MW:67.97 Appearance: White powder Related substance: Total Impurities(%) < 2.0% Acetate content: < 15.0% PURITY:98% STORAGE:yophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18°C. Upon reconstitution of the peptide it should be stored at 4°C between 2-21 days and for future use below -18°C. CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a hormone releasing hormone (GHRH) analog. Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects Another very positive benefit of CJC-1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC-1295, a long-acting hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH can induce significantly deeper sleep in a mouse. Various experiments have been conducted to test the effectiveness of CJC-1295. The Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased concentrations 1.5-3 fold for 9-11 days. The mean half life was 5.8-8.1 days and after multiple doses mean levels remained above baseline for up to 28 days following. No serious adverse reactions were reported in any group participating in this research study. This peptide has the ability to stimulate hormone very significantly.